Business·Industry

“Investment to Reach the High 40 Trillion Won Range This Year… M15X Mass Production Schedule to Be Accelerated”—SK hynix Conference Call

JAEMIN SONG
2026-07-29 09:43:39
[Edaily JAEMIN SONG Choi Oh-hyun Reporter] “We are executing investments to expand production capacity in response to robust customer demand and medium- to long-term growth opportunities. With accelerated timelines and expanded investment, we expect this year’s investment volume to reach the high 40 trillion won range. In the short term, to enhance our supply responsiveness, we are accelerating the mass production schedule for M15X and investing to ensure we can rapidly expand production capacity following the opening of the cleanroom at the first phase of the Yongin fab in early 2027. We also plan to establish the advanced packaging plant P&T7, the new NAND production base M17, and a new domestic semiconductor cluster to meet long-term demand over the medium to long term. “We will proceed in stages with actual fab construction, equipment deployment, and production capacity expansion, taking into comprehensive consideration factors such as the visibility of customer demand and investment efficiency. We will strengthen both our supply responsiveness and financial soundness while adhering to our capital expenditure principles.”

…SK hynix Q2 2026 Conference Call


A view of SK hynix’s headquarters in Icheon, Gyeonggi Province. (Photo: Yonhap News)

Economy

Corporation

IT·Science

Economy

Business Leaders Visit Brazil, a 'Market of 200 Million People'… Expanding Cooperation in Supply Chains, AI, and Beauty

Business leaders from South Korea and Brazil have agreed to expand cooperation across a wide range of strategic industries, from critical mineral supply chains to artificial intelligence (AI), biotech…
2026-07-29 11:32:11

Corporation

[Exclusive] Ingenia Puts New Kidney Drug on the Table for Technology Export... Hints at a “Trillion-Won” Mega Deal

Ingenia Therapeutics (Ingenia), an innovative antibody drug developer set to list on KOSDAQ, has brought a treatment for chronic kidney disease (CKD) to the negotiating table with a global big pharma …
2026-07-29 11:21:02

IT·Science

AHNLAB,INC. Reports First-Half Operating Profit of 7.3 Billion Won... Up 62.3% Year-Over-Year

AHNLAB,INC.(053800)announced preliminary financial results on the 29th, reporting consolidated revenue of 130.4 billion won and operating profit of 7.3 billion won for the first half of this year. …
2026-07-29 11:15:53